C-Rad AB (publ) (CRAD-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, C-Rad AB (publ) (CRAD-B) has a cash flow conversion efficiency ratio of 0.205x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr71.10 Million ≈ $7.65 Million USD) by net assets (Skr347.20 Million ≈ $37.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
C-Rad AB (publ) - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how C-Rad AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of C-Rad AB (publ) for a breakdown of total debt and financial obligations.
C-Rad AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C-Rad AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xtract One Technologies Inc.
TO:XTRA
|
-0.112x |
|
IMCO Industries Ltd
TA:IMCO
|
0.207x |
|
IF Bancorp Inc
NASDAQ:IROQ
|
0.018x |
|
Airtasker Ltd
AU:ART
|
1.179x |
|
DIRECTA SIM SPA
F:ZP7
|
N/A |
|
BEML LAND ASSETS LTD
NSE:BLAL
|
-0.017x |
|
Abcourt Mines Inc.
V:ABI
|
-3.289x |
|
Delfingen
PA:ALDEL
|
0.101x |
Annual Cash Flow Conversion Efficiency for C-Rad AB (publ) (2008–2025)
The table below shows the annual cash flow conversion efficiency of C-Rad AB (publ) from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see C-Rad AB (publ) (CRAD-B) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr347.20 Million ≈ $37.36 Million |
Skr71.10 Million ≈ $7.65 Million |
0.205x | +121.28% |
| 2024-12-31 | Skr324.99 Million ≈ $34.97 Million |
Skr30.08 Million ≈ $3.24 Million |
0.093x | -21.94% |
| 2023-12-31 | Skr281.60 Million ≈ $30.30 Million |
Skr33.38 Million ≈ $3.59 Million |
0.119x | +196.73% |
| 2022-12-31 | Skr242.54 Million ≈ $26.10 Million |
Skr9.69 Million ≈ $1.04 Million |
0.040x | -49.18% |
| 2021-12-31 | Skr231.09 Million ≈ $24.87 Million |
Skr18.17 Million ≈ $1.96 Million |
0.079x | -14.85% |
| 2020-12-31 | Skr199.79 Million ≈ $21.50 Million |
Skr18.45 Million ≈ $1.99 Million |
0.092x | -51.38% |
| 2019-12-31 | Skr83.33 Million ≈ $8.97 Million |
Skr15.83 Million ≈ $1.70 Million |
0.190x | +285.14% |
| 2018-12-31 | Skr93.64 Million ≈ $10.08 Million |
Skr-9.61 Million ≈ $-1.03 Million |
-0.103x | -82.21% |
| 2017-12-31 | Skr71.41 Million ≈ $7.68 Million |
Skr-4.02 Million ≈ $-432.62K |
-0.056x | +91.09% |
| 2016-12-31 | Skr70.60 Million ≈ $7.60 Million |
Skr-44.62 Million ≈ $-4.80 Million |
-0.632x | -10.29% |
| 2015-12-31 | Skr40.05 Million ≈ $4.31 Million |
Skr-22.95 Million ≈ $-2.47 Million |
-0.573x | -38.13% |
| 2014-12-31 | Skr40.04 Million ≈ $4.31 Million |
Skr-16.61 Million ≈ $-1.79 Million |
-0.415x | +30.97% |
| 2013-12-31 | Skr38.03 Million ≈ $4.09 Million |
Skr-22.86 Million ≈ $-2.46 Million |
-0.601x | +25.17% |
| 2012-12-31 | Skr16.26 Million ≈ $1.75 Million |
Skr-13.06 Million ≈ $-1.41 Million |
-0.803x | -41.62% |
| 2011-12-31 | Skr36.02 Million ≈ $3.88 Million |
Skr-20.43 Million ≈ $-2.20 Million |
-0.567x | -444.26% |
| 2010-12-31 | Skr48.12 Million ≈ $5.18 Million |
Skr-5.01 Million ≈ $-539.60K |
-0.104x | +64.39% |
| 2009-12-31 | Skr29.82 Million ≈ $3.21 Million |
Skr-8.73 Million ≈ $-939.06K |
-0.293x | -2.01% |
| 2008-12-31 | Skr35.05 Million ≈ $3.77 Million |
Skr-10.06 Million ≈ $-1.08 Million |
-0.287x | -- |
About C-Rad AB (publ)
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more